This biotech stock could see 138% upside as its lead asset reaches regulatory approval, Goldman Sachs said. Originally published at CNBC
Find More
Trending News
- PlayStation Will Remove Discovery Shows Despite User Purchase
- Protocol Village: Beam to Launch on Immutable zkEVM, Gaming-Focused L2 With Polygon Tech
- Putin Travels to U.A.E. and Saudi Arabia on Rare Trip to Mideast
- CZ’s Guilty Plea Accepted by Judge, Has Yet to Decide If Binance Founder Can Go Home
- Crypto Exchange Bitzlato Co-Founder Pleads Guilty to U.S. Money Transmitter Charge
- Commercial companies to collaborate for DARPA’s new lunar economy study
- As Bitcoin reaches the $44,000 threshold, why the surge and what’s next?
- Illia Kyva Is Killed Near Moscow
- Pro-Blockchain Bill Clears Hurdle in U.S. House
- New U.K. Asylum Bill Aims to Override Some Human Rights Law